Company Overview and News

 
D-Street Buzz: Nifty IT, pharma outperforms led by KPIT Tech, Dr Reddy#39;s Labs; auto drags

2018-10-15 moneycontrol
The Indian benchmark indices are trading in the red this Monday morning with the Nifty50 down 25 points, trading at 10,446 while the Sensex shed 47 points at 34,685.
IOC BAJAJ-AUTO 500408 500325 524816 RELIANCE TCHQY 532218 532977 532755 CADILAHC 535789 505200 SOUTHBANK 532343 532321 NATCOPHARM PINCON RIGD GAILF EICHERMOT RLNIY ECQRY 538771 TVSMOTOR IDKQY 530965 CDLYY TECHM IBULHSGFIN GAILY TATAELXSI DCMSHRIRAM 523367

 
Pincon Spirit Limited - Updates

2018-08-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
538771 PINCON

 
USL, GM Breweries, Pincon Spirit fall 5-6% after Karnataka govt raises excise duty on liquor

2018-07-05 moneycontrol
Share prices of all listed liquor companies fell up to 6 percent intraday on Thursday after the Karnataka government increased additional excise duty on liquor.
532432 538771 PINCON UBL UNITDSPR UQNTY UBHOLDINGS GLOBUSSPR 507458 UNBWY 532478 533104

 
Stocks that have been on a downtrend over last 8 trading sessions

2018-07-04 moneycontrol
Indian benchmark indices witnessed a good up move Wednesday after a series of volatile sessions over the last week. However, these 8 stocks have been steadily declining over the past 8 sessions.
GOLDTECH 538771 PINCON 531816 PANORAMUNI 506194 JBFIND 530381 531439 514034 ASL PETRONENGG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...